Back to resources

Resources

Displaying 1 - 8 of 178

CPHI Milan 2026: Investment Is Only Half the Story
CPHI Milan is always a useful barometer for where the pharmaceutical manufacturing indu...

By Charlotte Hirst October 20th, 2026
Cell and Gene Therapy Recruitment: Hiring Ahead of the Milestone
From IND and pivotal trials to regulatory approval and commercial launch, successful cell an...

By Holly Wallner October 15th, 2026
CPHI Milan 2026: 3 Takeaways as the CDMO Market Bounces Back
The CDMO market has its confidence back. That was the clearest message from CPHI Milan 2026,...

By Austin Hodgson October 15th, 2026
The UK Life Sciences Permanent Market Just Turned For The First Time in Four Years
Permanent placements in the UK rose last month. That hasn't happened since September 202...

By Barrington James October 1st, 2026
CGT manufacturing scalability and automation.
Scale is no longer a problem for after approval. It is part of the case.Cell and gene therap...

By Holly Wallner September 28th, 2026
Ex vivo vs in vivo CAR-T and gene therapy.
Autologous cell therapy works, 17 approved by the FDA so far, the constraint has always been...

By Holly Wallner September 28th, 2026
Medical Device
The FDA’s Next Decade Will Reshape Device Regulatory Hiring
CDRH Signals a Decade-Long Regulatory Science AgendaOn 25 September, the FDA's Center for De...

By Barrington James September 21st, 2026
From Funding to Regulation: The Talent Challenges Reshaping Digital Health.
Digital Health Funding Rebounded into Fewer HandsThe funding winter is over, though the thaw...

By Barrington James & Kyle Nelson September 14th, 2026